Bernadette Connaughton - Net Worth and Insider Trading

Bernadette Connaughton Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bernadette Connaughton owns 3 companies in total, including Syneos Health Inc (SYNH) , Halozyme Therapeutics Inc (HALO) , and Editas Medicine Inc (EDIT) .

Click here to see the complete history of Bernadette Connaughton’s form 4 insider trades.

Insider Ownership Summary of Bernadette Connaughton

Ticker	Comapny	Transaction Date	Type of Owner
SYNH	Syneos Health Inc	2021-05-12	director
HALO	Halozyme Therapeutics Inc	2018-09-07	director
EDIT	Editas Medicine Inc	2021-10-26	director

Bernadette Connaughton Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Bernadette Connaughton Ownership Network

Ownership Network List of Bernadette Connaughton

No Data

Ownership Network Relation of Bernadette Connaughton

Bernadette Connaughton Owned Company Details

What does Syneos Health Inc do?

Who are the key executives at Syneos Health Inc?

Bernadette Connaughton is the director of Syneos Health Inc. Other key executives at Syneos Health Inc include Chief Financial Officer Michael J. Bonello , See remarks Stanford Rudnick , and Chief Business Officer Christian Tucat .

Syneos Health Inc (SYNH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Syneos Health Inc (SYNH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Syneos Health Inc (SYNH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Syneos Health Inc (SYNH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syneos Health Inc Insider Transactions

No Available Data

What does Halozyme Therapeutics Inc do?

Who are the key executives at Halozyme Therapeutics Inc?

Bernadette Connaughton is the director of Halozyme Therapeutics Inc. Other key executives at Halozyme Therapeutics Inc include SVP & Chief Technical Officer Michael J. Labarre , director & President and CEO Helen Torley , and SVP & Chief Financial Officer Nicole Labrosse .

Halozyme Therapeutics Inc (HALO) Insider Trades Summary

Over the past 18 months, Bernadette Connaughton made no insider transaction in Halozyme Therapeutics Inc (HALO). Other recent insider transactions involving Halozyme Therapeutics Inc (HALO) include a net sale of 280,000 shares made by Michael J. Labarre , a net sale of 200,000 shares made by Helen Torley , and a net sale of 49,881 shares made by Matthew L. Posard .

In summary, during the past 3 months, insiders sold 199,881 shares of Halozyme Therapeutics Inc (HALO) in total and bought 0 shares, with a net sale of 199,881 shares. During the past 18 months, 584,881 shares of Halozyme Therapeutics Inc (HALO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 584,881 shares.

Halozyme Therapeutics Inc (HALO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Halozyme Therapeutics Inc Insider Transactions

No Available Data

What does Editas Medicine Inc do?

Who are the key executives at Editas Medicine Inc?

Bernadette Connaughton is the director of Editas Medicine Inc. Other key executives at Editas Medicine Inc include SVP & CHIEF MEDICAL OFFICER Baisong Mei , director & CEO Gilmore Neil O'neill , and EVP & CHIEF SCIENTIFIC OFFICER Linda Burkly .

Editas Medicine Inc (EDIT) Insider Trades Summary

Over the past 18 months, Bernadette Connaughton made no insider transaction in Editas Medicine Inc (EDIT). Other recent insider transactions involving Editas Medicine Inc (EDIT) include a net sale of 1,988 shares made by Bruce Eaton , a net sale of 32,292 shares made by Baisong Mei , and a net sale of 98,056 shares made by Gilmore Neil O'neill .

In summary, during the past 3 months, insiders sold 2,073 shares of Editas Medicine Inc (EDIT) in total and bought 0 shares, with a net sale of 2,073 shares. During the past 18 months, 166,559 shares of Editas Medicine Inc (EDIT) were sold and 45,000 shares were bought by its insiders, resulting in a net sale of 121,559 shares.

Editas Medicine Inc (EDIT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Editas Medicine Inc Insider Transactions

No Available Data

Bernadette Connaughton Mailing Address

Above is the net worth, insider trading, and ownership report for Bernadette Connaughton. You might contact Bernadette Connaughton via mailing address: C/o Visterra, Inc., One Kendall Square, #b3301, Cambridge Ma 02139.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.